17.33
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$16.40
Aprire:
$16.75
Volume 24 ore:
486.43K
Relative Volume:
1.44
Capitalizzazione di mercato:
$320.52M
Reddito:
$62.81M
Utile/perdita netta:
$-13.75M
Rapporto P/E:
-21.66
EPS:
-0.8
Flusso di cassa netto:
$153.00K
1 W Prestazione:
+38.86%
1M Prestazione:
+36.46%
6M Prestazione:
+175.52%
1 anno Prestazione:
+100.35%
Optimizerx Corp Stock (OPRX) Company Profile
Nome
Optimizerx Corp
Settore
Industria
Telefono
248-651-6558
Indirizzo
260 CHARLES STREET, WALTHAM, MI
Confronta OPRX con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
OPRX
Optimizerx Corp
|
17.33 | 300.38M | 62.81M | -13.75M | 153.00K | -0.80 |
![]()
VEEV
Veeva Systems Inc
|
279.18 | 45.26B | 2.86B | 780.66M | 1.20B | 4.72 |
![]()
TEM
Tempus Ai Inc
|
69.63 | 10.57B | 803.32M | -709.10M | -212.68M | -7.8003 |
![]()
DOCS
Doximity Inc
|
64.02 | 11.58B | 550.17M | 201.35M | 232.07M | 1.00 |
![]()
HQY
Healthequity Inc
|
89.27 | 8.00B | 1.15B | 96.70M | -161.99M | 1.09 |
![]()
WAY
Waystar Holding Corp
|
35.35 | 6.01B | 906.14M | -52.62M | 89.62M | -0.3621 |
Optimizerx Corp Stock (OPRX) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-01-08 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
2024-12-20 | Iniziato | Stephens | Equal-Weight |
2024-07-25 | Ripresa | B. Riley Securities | Buy |
2024-04-04 | Iniziato | JMP Securities | Mkt Outperform |
2024-01-03 | Iniziato | Barclays | Equal Weight |
2023-02-02 | Ripresa | B. Riley Securities | Buy |
2022-11-01 | Iniziato | Stifel | Buy |
2022-07-15 | Iniziato | SVB Leerink | Outperform |
2021-10-18 | Ripresa | B. Riley Securities | Buy |
2021-04-13 | Iniziato | RBC Capital Mkts | Outperform |
2019-01-03 | Iniziato | William Blair | Outperform |
Mostra tutto
Optimizerx Corp Borsa (OPRX) Ultime notizie
OptimizeRx’s SWOT analysis: digital health firm’s stock faces scaling hurdles - Investing.com
JMP Securities Forecasts Strong Price Appreciation for OptimizeRx (NASDAQ:OPRX) Stock - Defense World
OptimizeRx Corporation (NASDAQ:OPRX) Q2 2025 Earnings Call Transcript - Insider Monkey
JMP Securities Raises OptimizeRx (NASDAQ:OPRX) Price Target to $20.00 - MarketBeat
Is OptimizeRx Corporation stock bottoming outTechnical Trend Forecast for Investors - Newser
OptimizeRX price target raised to $20 from $14 at JMP on strong earnings - Investing.com Nigeria
Will breakout in OptimizeRx Corporation lead to full recoveryReal-Time Signal Tracking with Entry Level - Newser
What technical models suggest about OptimizeRx Corporation’s comebackDaily Stock Watch Summary with Key Insights - Newser
Can you recover from losses in OptimizeRx CorporationAI Short-Term Gain Forecast with Data - Newser
What makes OptimizeRx Corporation stock price move sharplySwing Trade Timing with Daily Forecast - Newser
Using AI based signals to follow OptimizeRx CorporationSteady Return Plan Based on Data Analysis - Newser
Trend analysis for OptimizeRx Corporation this weekFree Daily Growth Stock Pick Reports - Newser
Should you hold or exit OptimizeRx Corporation nowTechnical Screener for High Growth Stocks - Newser
Blair William & Co. IL Buys 29,648 Shares of OptimizeRx Corp. (NASDAQ:OPRX) - MarketBeat
Applying Elliott Wave Theory to OptimizeRx CorporationShort Term Gain Strategy with AI Logic - Newser
OptimizeRx Corp. (OPRX) Surpasses Q2 Earnings and Revenue Estimates - MSN
Stifel Nicolaus Forecasts Strong Price Appreciation for OptimizeRx (NASDAQ:OPRX) Stock - MarketBeat
Advanced analytics toolkit walkthrough for OptimizeRx CorporationTechnical Reversal Pattern Summary and Tracker - Newser
OptimizeRx Reports Strong Q2 2025 Financial Growth - The Globe and Mail
Healthcare Stocks Move in Friday's Pre-Market Session: OptimizeRx, Embecta, and More - AInvest
OptimizeRx Corp Surpasses Q2 2025 Estimates with 55% Revenue Increase, Achieves GAAP Net Income of $1.5M - AInvest
Stifel raises Optimizerx PT to $18, maintains Buy rating. - AInvest
Earnings call transcript: OptimizeRx Q2 2025 sees EPS surprise, stock jumps - Investing.com Nigeria
OptimizeRx Corp (OPRX) Q2 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
OptimizeRx Corp reports results for the quarter ended June 30Earnings Summary - TradingView
OptimizeRx Stock Rallies 22% After-Hours Thanks To Q2 Earnings Push - inkl
OPTIMIZERx earnings beat by $0.22, revenue topped estimates - Investing.com
OptimizeRx Q2 rev up 55% YoY to $29.2mln, raises FY25 guidance. - AInvest
OptimizeRx Reports Second Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance - The Manila Times
Press Release: OptimizeRx Reports Second Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance - 富途牛牛
Best Growth Stocks to Buy for August 7th - TradingView
Technical analysis overview for OptimizeRx Corporation stockTrend Reversal Watch with Entry Signals - Newser
Has OptimizeRx Corporation formed a bullish divergenceEntry Opportunity Screener with Confirmation - Newser
OptimizeRx Corp expected to post earnings of 2 cents a shareEarnings Preview - TradingView
Best Growth Stocks to Buy for August 5th - TradingView
OptimizeRx (OPRX) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Is OptimizeRx Corporation stock overvalued or undervaluedExceptional portfolio growth - Jammu Links News
Why is OptimizeRx Corporation stock attracting strong analyst attentionMaximize returns with strategic stock selection - Jammu Links News
How volatile is OptimizeRx Corporation stock compared to the marketMaximize returns with timely market signals - Jammu Links News
Should I hold or sell OptimizeRx Corporation stock in 2025Get real-time alerts on high-potential stocks - Jammu Links News
Best Growth Stocks to Buy for August 1st - Yahoo Finance
Published on: 2025-08-01 01:36:35 - Newser
Bull Of The Day: OptimizeRX (OPRX) - The Globe and Mail
Does OptimizeRx Have a Moat in the Crowded HealthTech Space? - Yahoo Finance
Optimizerx Corp Azioni (OPRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Optimizerx Corp Azioni (OPRX) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Silvestro Stephen L | Chief Commercial Officer |
Mar 01 '25 |
Option Exercise |
0.00 |
1,928 |
0 |
121,886 |
Odence-Ford Marion | Chief Legal Officer & CHRO |
Mar 01 '25 |
Option Exercise |
0.00 |
771 |
0 |
70,544 |
KLEMA CATHY | Director |
Feb 02 '25 |
Option Exercise |
0.00 |
5,109 |
0 |
11,752 |
Odence-Ford Marion | General Counsel and CCO |
Dec 19 '24 |
Option Exercise |
0.00 |
3,927 |
0 |
28,383 |
Silvestro Stephen L | Chief Commercial Officer |
Dec 19 '24 |
Option Exercise |
0.00 |
6,546 |
0 |
83,424 |
Besch Doug | Chief Product Officer |
Dec 19 '24 |
Option Exercise |
0.00 |
1,964 |
0 |
12,160 |
Stelmakh Edward | CFO/COO |
Dec 19 '24 |
Option Exercise |
0.00 |
5,237 |
0 |
38,603 |
FEBBO WILLIAM J | CEO |
Dec 12 '24 |
Buy |
5.01 |
20,000 |
100,220 |
601,253 |
Odence-Ford Marion | General Counsel and CCO |
Nov 08 '24 |
Option Exercise |
0.00 |
1,785 |
0 |
24,980 |
Stelmakh Edward | CFO/COO |
Oct 11 '24 |
Option Exercise |
0.00 |
8,222 |
0 |
35,432 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):